Active Biotech - extra shareholders- meeting 19 october 2000

10/19/2000 12:45 EST

ACTIVE BIOTECH - EXTRA SHAREHOLDERS´ MEETING 19 OCTOBER 2000

At Active Biotech´s extra shareholders´meeting today, it was decided that
the number of members of the board should be increased, from eight to nine
and to elect the following new directors:

Mats Arnhög (born 1951).
Mats Arnhög has a Master of Science in Business and Economics from
Stockholm School of Economics, and is the current owner of the company MGA
Holding. Mats Arnhög is, through MGA Holding, one of the major
shareholders in Active Biotech with 6,1% of share capital and 28,9% of
votes. In addition to his board appointments in different subsidiaries of
MGA Holding, Mats Arnhög is also a Member of the Board in K-World.

Maria Borelius (born 1960).
Maria Borelius has a Bachelor of Science in Biology with a Masters degree
in Science journalism. She has experience from Sveriges Television,
Sveriges Radio, TV4 and TV3, from programmes such as NOVA, Vetenskapens
Värld and Vetandets Värld.
Maria Borelius is part-owner and Senior Vice President of Learning
Development, K-World, an Internet based knowledge- and educational
company. Maria Borelius is a Member of the Board in Naturvetenskapliga
Forskningrådet.

Peter Sjöstrand (born 1946).
Peter Sjöstrand has a Master of Science in Business and Economics from
Stockholm School of Economics and is a Medical Doctor, with 20 years
experience from association with Astra´s Board and Management, latest as
Vice President (1988-93). Peter Sjöstrand is mainly active abroad, as
Member of the Board in Pharma Vision AG, Switzerland and Tularik Inc.,
USA. In Sweden he is Chairman of the Board in Meda AB.

In relation to the extra shareholders´ meeting, Karl Olof Borg and Else-
Maj Rosenlöf have left their board appointments at Active Biotech AB.

After the meeting, the board has the following composition:
Hugo Thelin, Chairman of the Board, Sven Andréasson, Mats Arnhög, Maria
Borelius,
Svend Holst-Nielsen, Mats Pettersson, Peter Sjöstrand, Anders Williamsson
and Håkan Åström. The employee's representatives of the Board are Anders

Hagberg and Hans Wännman.
Lund 19 October 2000
Active Biotech AB (publ)
Sven Andréasson, President & CEO

Active Biotech AB is a Swedish biotechnology company focused on the
research and
development of pharmaceuticals and vaccines, the core competence being
knowledge of the
human immune system. Active Biotech has a high quality project portfolio
and financial strength. Important products and projects include Dukoral,
SBLCholera Vaccine, a vaccine against traveller's diarrhoea (ETEC), drugs
against multiple sclerosis (SAIK) and cancer (TTS). The turnover of Active
Biotech was SEK 267 million in 1999.

Active Biotech AB
Box 724, S-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46 19 20 50
E-mail